StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) stock

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.63−0.01 (-1.39%)

Close on Nov 17, 2026Market cap $59.90MP/E –Yield –

Cognition Therapeutics cash

Cash and short-term investments held at the end of each period.

Cognition Therapeutics's cash was $34.01M at Jun 30, 2026. For fiscal 2025 it was $36.81M, up 47.2% from the year before. The highest annual figure on record is $54.72M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$36.81M+47.2%
FY2024Dec 31, 2024$25.01M-16.4%
FY2023Dec 31, 2023$29.92M-28.0%
FY2022Dec 31, 2022$41.56M-24.0%
FY2021Dec 31, 2021$54.72M+954.6%
FY2020Dec 31, 2020$5.19M+79.6%
FY2019Dec 31, 2019$2.89M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$34.01M+216.6%
Q1 FY2026Mar 31, 2026$31.13M+89.5%
Q4 FY2025Dec 31, 2025$36.81M+47.2%
Q3 FY2025Sep 30, 2025$39.33M+78.7%
Q2 FY2025Jun 30, 2025$10.74M-62.3%
Q1 FY2025Mar 31, 2025$16.43M-52.6%
Q4 FY2024Dec 31, 2024$25.01M-16.4%
Q3 FY2024Sep 30, 2024$22.01M-33.2%
Q2 FY2024Jun 30, 2024$28.53M-23.3%
Q1 FY2024Mar 31, 2024$34.67M-10.7%
Q4 FY2023Dec 31, 2023$29.92M-28.0%
Q3 FY2023Sep 30, 2023$32.97M-29.3%
Q2 FY2023Jun 30, 2023$37.19M-18.7%
Q1 FY2023Mar 31, 2023$38.81M-24.7%
Q4 FY2022Dec 31, 2022$41.56M-24.0%
Q3 FY2022Sep 30, 2022$46.61M+460.9%
Q2 FY2022Jun 30, 2022$45.77M+305.1%
Q1 FY2022Mar 31, 2022$51.51M+285.2%
Q4 FY2021Dec 31, 2021$54.72M+954.6%
Q3 FY2021Sep 30, 2021$8.31M+58.5%
Q2 FY2021Jun 30, 2021$11.30M+291.0%
Q1 FY2021Mar 31, 2021$13.37M–
Q4 FY2020Dec 31, 2020$5.19M–
Q3 FY2020Sep 30, 2020$5.24M–
Q4 FY2019Dec 31, 2019$2.89M–

More Cognition Therapeutics figures

See a number that looks wrong?